Why R&D Innovation will continue to be at the core of GSK's business.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Why R&D Innovation will continue to be at the core of GSK's business.
Released on: September 03, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Following the Novartis transaction GSK is now the leading company in vaccines, consumer health care and over the counter medicines.
  • Summary
  • Transcript
  • Company
Following the Novartis transaction GSK is now the leading company in vaccines, consumer health care and over the counter medicines. During BIO 2015, Luigi La Corte, SVP Finance & Head of WWBD, Pharma R&D at GSK told Fintan Walton, CEO of PharmaVenture, about how R&D innovation will continue to leverage business development and advance their strategy in various therapeutic areas.
Following the Novartis transaction GSK is now the leading company in vaccines, consumer health care and over the counter medicines. During BIO 2015, Luigi La Corte, SVP Finance & Head of WWBD, Pharma R&D at GSK told Fintan Walton, CEO of PharmaVenture, about how R&D innovation will continue to leverage business development and advance their strategy in various therapeutic areas.
GlaxoSmithKline (GSK)
GSK is the world's second largest pharmaceutical company, by employees; and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines.